- •High dose-rate brachytherapy (HDR) has low rate of late urinary or bowel toxicity.
- •Grade 3 urinary toxicity was rare and only seen after single fraction.
- •No detriment in urinary quality of life after the first year with two fraction HDR.
- •Single fraction HDR resulted in decreased urinary quality of life at 4 and 5 years.
Background and Purpose
Materials and Methods
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- High dose-rate brachytherapy in the treatment of prostate cancer.Transl. Androl. Urol. 2018; 7: 357-370https://doi.org/10.21037/tau.2017.12.08
- The evolution of brachytherapy for prostate cancer.Nat Rev Urol. 2017; 14: 415-439https://doi.org/10.1038/nrurol.2017.76
- Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: Analysis of over 500 patients.Radiother Oncol. 2019; 141: 149-155https://doi.org/10.1016/j.radonc.2019.08.017
- High-dose-rate brachytherapy boost for prostate cancer: rationale and technique.J Contemp Brachytherapy. 2014; 6: 323-330https://doi.org/10.5114/jcb.2014.45759
- Long-term toxicity and health-related quality of life after single-fraction high dose rate brachytherapy boost and hypofractionated external beam radiotherapy for intermediate-risk prostate cancer.Clinical Oncology. 2017; 29: 412-420https://doi.org/10.1016/j.clon.2017.01.042
National Comprehensive Cancer Network. Prostate Cancer (Version 1.2020). https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed April 28, 2020. n.d.
- High dose rate brachytherapy for prostate cancer: A prospective toxicity evaluation of a one day schedule including two 13.5 Gy fractions.Radiother Oncol. 2018; 127: 219-224https://doi.org/10.1016/j.radonc.2018.03.022
- Patient and physician reported toxicity with two-fraction definitive high-dose-rate prostate brachytherapy: the impact of implant interval.J Contemp Brachytherapy. 2020; 12: 216-224https://doi.org/10.5114/jcb.2020.96861
- Early toxicity and health-related quality of life results of high-dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer.Brachytherapy. 2018; 17: 524-529https://doi.org/10.1016/j.brachy.2018.01.009
- Two-fraction high-dose-rate brachytherapy within a single day combined with external beam radiotherapy for prostate cancer: Single institution experience and outcomes.J Radiat Res. 2016; 57: 280-287https://doi.org/10.1093/jrr/rrw003
- Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.Radiother Oncol. 2020; 146: 90-96https://doi.org/10.1016/j.radonc.2020.02.009
- Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.Radiother Oncol. 2017; 122: 87-92https://doi.org/10.1016/j.radonc.2016.10.019
- The clinical value and meaning of health-related quality-of-life outcomes in oncology.Cambridge University Press, Cambridge2005
- HDR prostate brachytherapy.Semin Radiat Oncol. 2020; 30: 49-60https://doi.org/10.1016/j.semradonc.2019.08.003
- Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer.Radiother Oncol. 2020; 147: 123-129https://doi.org/10.1016/j.radonc.2020.03.033
- Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<60 cc) and large (≥60 cc) prostate glands.Brachytherapy. 2019; 18: 13-21https://doi.org/10.1016/j.brachy.2018.08.009
- High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores.Brachytherapy. 2019; 18: 793-799https://doi.org/10.1016/j.brachy.2019.06.001
- Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localised prostate cancer: Early results of a UK national cohort study.Radiother Oncol. 2020; 143: 95-100https://doi.org/10.1016/j.radonc.2019.12.017
- High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results.Radiother Oncol. 2016; 119: 411-416https://doi.org/10.1016/j.radonc.2016.04.006
- Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients.Int J Radiat Oncol Biol Phys. 2007; 69: 95-102https://doi.org/10.1016/j.ijrobp.2007.02.034
- Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients.Brachytherapy. 2009; 8: 210-217https://doi.org/10.1016/j.brachy.2008.11.010
- Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.Int J Radiat Oncol Biol Phys. 2009; 73: 1023-1032https://doi.org/10.1016/j.ijrobp.2008.05.022
- A phase 2 randomized pilot study comparing high-dose-rate brachytherapy and low-dose-rate brachytherapy as monotherapy in localized prostate cancer.Adv Radiat Oncol. 2019; 4: 631-640https://doi.org/10.1016/j.adro.2019.04.003
- Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?.Int J Radiat Oncol Biol Phys. 2006; 64: 825-834https://doi.org/10.1016/j.ijrobp.2005.04.056
- Estimating acute urinary retention risk post prostate high dose-rate (HDR) brachytherapy: A clinical-based recursive partitioning analysis.Radiother Oncol. 2021; 154: 118-122https://doi.org/10.1016/j.radonc.2020.09.023
- Impotence and Its medical and psychosocial correlates: results of the Massachusetts male aging study.J Urol. 1994; 151: 54-61https://doi.org/10.1016/S0022-5347(17)34871-1
- A comparative study of quality of life in patients with localized prostate cancer treated at a single institution: Stereotactic ablative radiotherapy or external beam+high dose rate brachytherapy boost.Radiother Oncol. 2014; 113: 404-409https://doi.org/10.1016/j.radonc.2014.10.013
- Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer : outcomes from two clinical trials with and without an MRI- guided boost.Radiother Oncol. 2020; 154: 29-35https://doi.org/10.1016/j.radonc.2020.09.007
- A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer.Radiother Oncol. 2007; 84: 135-139https://doi.org/10.1016/j.radonc.2007.05.020
- Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer.Cancer. 2007; 109: 2239-2247https://doi.org/10.1002/cncr.22676
- Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: A systematic review of the literature.Cancer. 2007; 110: 1417-1428https://doi.org/10.1002/cncr.22941
- A novel salvage option for local failure in prostate cancer, reirradiation using external beam or stereotactic radiotherapy: systematic review and meta-analysis.Adv Radiat Oncol. 2020; https://doi.org/10.1016/J.ADRO.2020.04.022
- Focal salvage high dose-rate brachytherapy for locally recurrent prostate cancer after primary radiation therapy failure: results from a prospective clinical trial.Int J Radiat Oncol Biol Phys. 2018; 102: 561-567https://doi.org/10.1016/j.ijrobp.2018.06.039
Canadian Clinical Trials Group. Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer (PR19). In:ClinicalTrials.gov, 2000-2020. Bethesda (MD): National Library n.d. https://clinicaltrials.gov/ct2/show/NCT02960087 (accessed October 5, 2020).
- Declining use of brachytherapy for the treatment of prostate cancer.Brachytherapy. 2014; 13: 157-162https://doi.org/10.1016/j.brachy.2013.08.005
- The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness.Brachytherapy. 2016; 15: 701-706https://doi.org/10.1016/j.brachy.2016.05.001
- Is prostate brachytherapy a dying art? Trends and variation in the definitive management of prostate cancer in Ontario, Canada.Radiother Oncol. 2020; 152: 42-48https://doi.org/10.1016/j.radonc.2020.07.036